title: D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients.
authors.forename: T
authors.initials: T
authors.lastname: Leguay
authors.forename: V
authors.initials: V
authors.lastname: Desplat
authors.forename: G
authors.initials: G
authors.lastname: Marit
authors.forename: F-X
authors.initials: FX
authors.lastname: Mahon
mesh_terms: D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D017809:Fatal Outcome; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D020125:Mutation, Missense; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate